Jukka Westermarck
MD, PhD
jukka.westermarck@utu.fi +358 29 450 2880 +358 40 742 3007 Tykistökatu 6 Turku Työhuone: 4124 (B-stairs, 4th floor) ORCID-tunniste: https://orcid.org/0000-0001-7478-3018 |
Role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers
Jukka Westermarck is a Professor of Cancer Biology, and Research Director, in the Turku Bioscience Centre at University of Turku.
Westermarck earned his medical degree from University of Turku in 1996. Two years later he obtained his PhD degree in Department of Medical Biochemistry and Department of Dermatology at the same University. He was working as a postdoctoral fellow in the laboratory of Dirk Bohmann during 1999-2001 in the European Molecular Biology Laboratory in Heidelberg, Germany. After being appointed as Academy Fellow by the Academy of Finland, he established his own research group at Turku Centre for Biotechnology in 2002. In 2006-2009 he was appointed as a group leader in the Institute of Medical Technology at University of Tampere, and after that he returned back to Turku due to his appointment as a tenure Research Director of Turku Centre for Biotechnology, and as a Professor of Cancer Biology at the Faculty of Medicine. In 2012, he worked as a visiting Professor at Dana-Farber Cancer Institute, Boston.
Professor Westermarck received young researcher prize from Finnish Medical Association Duodecim 2007, and Anders Jahre young investigator prize 2009 from University of Oslo, Norway. In 2017, he became an elected member of the Finnish Academy of Science and Letters.
Prof. Westermarck´s research focuses on role and regulation of phosphatases, particularly tumor suppressor protein phosphatase 2A (PP2A) in human cancers. Based on this work his group has identified several novel signaling principles how PP2A regulates cancer progression, as well as potential novel cancer therapy targets and diagnostic biomarkers.
- Evaluation of prognostic biomarkers in a population-validated Finnish HNSCC patient cohort (2021)
- European Archives of Oto-Rhino-Laryngology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Fosfataasien avulla syövän kimppuun (2021)
- DuodecimBrain Communications
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - (2021)
- CellJournal of Biological Chemistry
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - (2S, 4R)-4-[18F]Fluoroglutamine for In vivo PET Imaging of Glioma Xenografts in Mice: an Evaluation of Multiple Pharmacokinetic Models (2020)
- Molecular Imaging and Biology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling (2020)
- iScience
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer's Disease Pathogenesis in Cell and Animal Models (2020)
- Neurotherapeutics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Good guy in bad company: How STRNs convert PP2A into an oncoprotein (2020)
- Cancer Cell
(B1 Vertaisarvioimaton kirjoitus tieteellisessä lehdessä ) - Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors (2020)
- Oncogene
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma (2020)
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1 (2020)
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )



